TY - JOUR
T1 - Measuring psoriatic disease in clinical practice. An expert opinion position paper
AU - Lubrano, Ennio
AU - Cantini, Fabrizio
AU - Costanzo, Antonio
AU - Girolomoni, Giampiero
AU - Prignano, Francesca
AU - Olivieri, Ignazio
AU - Scarpa, Raffaele
AU - Spadaro, Antonio
AU - Atzeni, Fabiola
AU - Narcisi, Alessandra
AU - Ricceri, Federica
AU - Sarzi-Puttini, Piercarlo
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Psoriasis is a common, immune-mediated chronic inflammatory disease with a primary involvement of skin and joints, affecting approximately 2% of the population worldwide. Up to one third of patients with psoriasis are diagnosed with psoriatic arthritis (PsA). Psoriasis and PsA are heterogeneous diseases whose severity depends on a number of clinical factors, such as areas affected and pattern of involvement, and are associated with a range of comorbid diseases and risk factors, including obesity, metabolic syndrome, cardiovascular disease and liver disease. Thus measuring the severity of psoriatic disease needs to take into account the multidimensional aspects of the disease. Subjective measures including the impairment in quality of life or in daily living activities as well as the presence of cardio-metabolic comorbidities, are important for the outcome and add further levels of complexity that, to a certain extent, need to be assessed. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented for a most effective managing of psoriasis patients. A joint dermatologist-rheumatologist roundtable discussion was convened to share evidence on the real-life use of methods for measuring psoriasis severity comprehensively. Our objective was to provide an expert position on which clinical variables are to be taken into account when considering patients affected by psoriasis and/or PsA globally and on the assessment tools more suitable for measuring disease activity and/or severity in clinical practice.
AB - Psoriasis is a common, immune-mediated chronic inflammatory disease with a primary involvement of skin and joints, affecting approximately 2% of the population worldwide. Up to one third of patients with psoriasis are diagnosed with psoriatic arthritis (PsA). Psoriasis and PsA are heterogeneous diseases whose severity depends on a number of clinical factors, such as areas affected and pattern of involvement, and are associated with a range of comorbid diseases and risk factors, including obesity, metabolic syndrome, cardiovascular disease and liver disease. Thus measuring the severity of psoriatic disease needs to take into account the multidimensional aspects of the disease. Subjective measures including the impairment in quality of life or in daily living activities as well as the presence of cardio-metabolic comorbidities, are important for the outcome and add further levels of complexity that, to a certain extent, need to be assessed. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented for a most effective managing of psoriasis patients. A joint dermatologist-rheumatologist roundtable discussion was convened to share evidence on the real-life use of methods for measuring psoriasis severity comprehensively. Our objective was to provide an expert position on which clinical variables are to be taken into account when considering patients affected by psoriasis and/or PsA globally and on the assessment tools more suitable for measuring disease activity and/or severity in clinical practice.
KW - Cardiovascular
KW - Comorbidities
KW - Metabolic syndrome
KW - Outcome measures
KW - Psoriasis
KW - Psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=84940614895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940614895&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2015.05.010
DO - 10.1016/j.autrev.2015.05.010
M3 - Article
C2 - 26025585
AN - SCOPUS:84940614895
VL - 14
SP - 864
EP - 874
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 10
ER -